We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proteomic Analysis of Human Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01177631
Recruitment Status : Completed
First Posted : August 9, 2010
Last Update Posted : February 5, 2016
Sponsor:
Information provided by (Responsible Party):
Meng-Tzu Weng, Far Eastern Memorial Hospital

Brief Summary:
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.

Condition or disease Intervention/treatment
Carcinoma, Hepatocellular Procedure: Operation

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis
Study Start Date : February 2009
Primary Completion Date : January 2010
Study Completion Date : January 2010

Intervention Details:
    Procedure: Operation
    Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.


Primary Outcome Measures :
  1. Recurrence [ Time Frame: one year ]
    Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Arm A: Hepatocellular carcinoma with vessel invasion:

  • hepatocellular carcionoma, pathologic diagnosed.
  • image documented vessel invasion, including portal vein thrombosis
  • eligible for surgical intervension.

Arm B: hepatocellular carcinoma without vessel invasion:

  • hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
  • no vessel invasion on image.

Arm C: Healthy hepatitis carrier:

  • patients age >18 years old with hepatitis B or C
  • normal liver function.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01177631


Locations
Taiwan
Far Eastern Memorial Hospital
Taipei, Taiwan, 220
Sponsors and Collaborators
Far Eastern Memorial Hospital

Responsible Party: Meng-Tzu Weng, Physician, Far Eastern Memorial Hospital
ClinicalTrials.gov Identifier: NCT01177631     History of Changes
Other Study ID Numbers: 97068
First Posted: August 9, 2010    Key Record Dates
Last Update Posted: February 5, 2016
Last Verified: February 2016

Keywords provided by Meng-Tzu Weng, Far Eastern Memorial Hospital:
Carcinoma, hepatocellular
Portal vein
Proteomics

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases